Cardiovasculaire Geneeskunde.nl

Wat betekent de komst van het eerste NOAC antidotum voor de klinische praktijk?

Dr. M. Coppens, dr. N. Bijsterveld, E. Wiltink

10' educatie - 10 dec. 2015 - Nieuwegein - Michiel Coppens, Nick Bijsterveld, Ed Wiltink

Video navigation menu

  • Inleiding orale antistolling en beschikbaarheid idarucizumab 01:17
  • Hoe vaak doen zich spoedoperaties of bloedingscomplicaties voor in de dagelijkse klinische praktijk?  06:43
  • Ziekenhuisprotocollen over antistolling en complicaties 07:45
  • Wat is de beste patiëntengroep die in aanmerking komt voor idarucizumab? 10:25
  • Moeten bloedwaarden bepaald worden alvorens een antidotum te geven? 12:09
  • Moet de arts de patiënt inlichten over de komst van dit eerste antidotum; wat is het perspectief van de patiënt? 15:25

Nu idarucizumab als eerste antidotum voor een NOAC op de markt is, bespreken een internist, een cardioloog en een ziekenhuisapotheker in welke situaties dit de klinische praktijk kan beïnvloeden.

De sprekers:
- Michiel Coppens, internist-vasculaire geneeskundige, AMC Amsterdam
- Nick Bijsterveld, cardioloog, Flevoziekenhuis, Almere
- Ed Wiltink, ziekenhuisapotheker, St Antonius Ziekenhuis, Nieuwegein

De productie werd mede mogelijk gemaakt door financiële ondersteuning van Boehringer Ingelheim.

De informatie en gegevens die verstrekt worden in dit programma zijn bijgewerkt en correct ten tijde van de ontwikkeling van het programma, maar zijn mogelijk onderhevig aan wijzigingen.

Deel deze pagina met collega's en vrienden:

:inherit;cursor:pointer;background-color:#dcdcdc}#gallery>a:nth-of-type(4n){margin-right:0}@media screen\0{#gallery>a{width:calc((99.99% - 3em)/ 4)}}@media screen and (orientation:portrait) and (max-width:800px){#gallery>a{width:calc((100% - 1em)/ 2);padding-bottom:calc((100% - 1em)/ 2)}#gallery>a:nth-of-type(2n){margin-right:0}}#gallery>a>img{display:none}#gallery:empty{display:none}#photoViewerView{position:fixed;left:0;right:0;bottom:0;top:0;z-index:1010;background-color:rgba(0,0,0,.9);overflow:hidden;line-height:0;-webkit-user-select:none;-webkit-text-size-adjust:none;user-select:none}#photoViewerView>#photoViewerScroller{width:200%;height:100%;position:relative;line-height:0;-webkit-user-select:none;-webkit-text-size-adjust:none;user-select:none}#photoViewerView>#photoViewerScroller>div{display:inline-block;width:50%;height:100%;color:#fff;text-align:center;line-height:100%;vertical-align:top;background-position:center;background-size:contain;background-repeat:no-repeat}#photoViewerInteraction{position:fixed;left:0;right:0;bottom:0;top:0;z-index:1011;-webkit-user-select:none;-webkit-text-size-adjust:none;user-select:none;box-sizing:border-box;cursor:pointer}#photoViewerInteraction,#photoViewerView{display:none}#playerContainer{display:flex;width:100%;position:relative;flex-direction:column}#player{flex:0 0 auto;display:inline-block;position:relative;width:100%;box-sizing:border-box;background-color:#000;line-height:0}#player>video{display:block;width:100%;height:auto}#zapper{flex:1 1 auto}#zapper>h1{display:block;font-size:.8em;font-family:OpenSans-Bold;text-transform:uppercase;padding:5px;line-height:100%;color:#fff;background-color:#444}#zapper ul{line-height:130%;font-size:.9em;padding:5px;margin-bottom:0}#zapper li{position:relative;cursor:pointer;padding-left:0;padding-bottom:.5em;margin-bottom:.5em}#zapper li:not(:last-child){border-bottom:1px solid rgba(100,100,100,.5)}#zapper li>span{font-family:OpenSans-Bold;color:#aaa;font-size:.8em}#zapper li>img{float:right;display:inline-block;height:1.5em;vertical-align:middle;margin-left:1em}#subtitles:empty{display:none}#subtitles{display:flex;justify-content:space-between;background-color:#444;height:50px}#subtitles>button{display:flex;align-items:center;flex-direction:column;font-family:OpenSans-Bold,sans-serif;text-transform:uppercase;color:#fff;font-size:.6em;background-color:transparent;border-radius:0;border:0;cursor:pointer;position:relative;padding:1em;margin-left:0;margin-right:0;margin-bottom:0}#subtitles>button:hover{background-color:rgba(220,220,220,.2)}#subtitles>button.active{background-color:#dcdcdc}#subtitles>button>img{flex:0;height:20px}#subtitles>button>label{vertical-align:middle;line-height:100%;margin-top:.2em}#subtitles>button.active>label{color:#000}@media screen and (max-width:400px){#subtitles>button>img{height:15px}#subtitles>button{font-size:.4em}}.videoStats{background-color:#f0f0f0;padding:10px;padding-top:40px;border:1px solid #000;position:relative;margin-top:1em}.videoStats>h1{background-color:#000;color:#fff;text-align:center;font-weight:400;font-size:14px;text-transform:uppercase;padding:5px;position:absolute;top:0;left:0;right:0}.videoStats>p{margin-bottom:0!important}.videoStats .heatContainer{border-bottom:1px solid rgba(140,140,140,.5)}.videoStats>p:last-of-type{margin-top:1em}.videoStats .heatContainer>div{font-size:8px;display:flex;justify-content:space-between;cursor:pointer}.videoStats .heatContainer>div:not(:last-child){border-bottom:1px solid rgba(255,255,255,.5)}.videoStats .heatContainer>div>span:last-child{text-align:right} #form>h1,#thanks{font-weight:400;margin-bottom:.2em}#form>p,#thanks{margin-bottom:1em}#form>div{display:block}#form>div>div{display:inline-block;width:calc(50% - .5em);position:relative}#form>div>div:nth-child(2n){margin-left:1em}@media screen and (min-width:700px){#interests>div{width:calc((100% / 4) - (3em / 4))!important;margin-right:1em;margin-left:0!important;box-sizing:border-box}#interests>div:nth-child(4n){margin-right:0!important}}div input{box-shadow:none;filter:none;background-image:none;outline:0}.textArea,.textBox{border-top:1px solid transparent;border-bottom:1px solid rgba(100,100,100,.5);border-left:1px solid transparent;border-right:1px solid transparent;font-family:OpenSans-Regular,sans-serif;font-size:14px;line-height:120%;color:#000;padding-left:5px;padding-right:5px;padding-top:5px;padding-bottom:5px;box-sizing:border-box;-webkit-appearance:none;border-radius:0;width:100%;outline:0;background-color:rgba(100,100,100,.1)}.textArea{height:5em}.textBox:focus .textArea:focus{box-shadow:none;outline:0}label{font-size:14px;font-family:OpenSans-Regular,sans-serif;line-height:120%;color:rgba(0,0,0,.5)}button{padding:5px;margin:0;border:none;border-radius:0;-webkit-appearance:none;-moz-appearance:none;background-color:transparent;outline:0;-webkit-box-shadow:none;-moz-box-shadow:none;box-shadow:none;background-image:none;filter:none}.greenButton,.normalButton,.redButton,.toggleButton{-webkit-appearance:none;font-family:OpenSans-Regular,sans-serif;outline:0;box-sizing:border-box;height:30px;font-size:14px;line-height:30px;text-transform:uppercase;font-weight:700;vertical-align:middle;letter-spacing:.1em;margin-top:15px;padding-top:0;padding-bottom:0;padding-left:15px;padding-right:15px;border:none;border-radius:0;color:#fff;transition:all .2s linear;cursor:pointer;-webkit-tap-highlight-color:transparent;user-select:none;-webkit-user-select:none;-moz-user-select:none}.normalButton{background-color:#000;border:1px solid #000}.greenButton{background-color:#32c832;border:1px solid #32c832}.redButton{background-color:#b00;border:1px solid #b00}select{border-top:1px solid transparent;border-bottom:1px solid rgba(100,100,100,.5);border-left:1px solid transparent;border-right:1px solid transparent;color:#000;padding-left:0;padding-right:5px;padding-top:5px;padding-bottom:5px;box-sizing:border-box;-webkit-appearance:none;-moz-appearance:none;appearance:none;font-family:OpenSans-Regular,sans-serif;font-size:14px;line-height:120%;background-image:none;border-image:none;white-space:normal;background-color:rgba(100,100,100,.1);text-indent:0;border-radius:0;width:100%;outline:0}@media screen and (min-color-index:0) and(-webkit-min-device-pixel-ratio:0){@media{select{text-indent:5px}}}select:focus option:focus{box-shadow:none;outline:0}select:-moz-focusring{color:transparent;text-shadow:0 0 0 #000}select option{padding:0;margin:0;background-color:rgba(100,100,100,.1);box-sizing:border-box;-webkit-appearance:none;font-family:OpenSans-Regular,sans-serif;font-size:12px;line-height:120%;border:none}.fileControl{position:relative;padding-top:20px;margin-bottom:10px;display:block;box-shadow:none;filter:none;background-image:none;outline:0}.fileControl label{position:absolute;top:0;left:0;font-size:14px;line-height:100%}.fileControl input{display:none}.fileControl .addButton{display:inline-block;cursor:pointer;background-color:rgba(200,200,200,.2);vertical-align:top;line-height:0}.fileControl .addButton.ready{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAQAAAAEAAgMAAAAhHED1AAAACXBIWXMAAAsTAAALEwEAmpwYAAAAB3RJTUUH3wcIDDIeRk1g0wAAABl0RVh0Q29tbWVudABDcmVhdGVkIHdpdGggR0lNUFeBDhcAAAAJUExURQAAAAAAAP///4Pdz9IAAAABdFJOUwBA5thmAAAAAWJLR0QCZgt8ZAAAAGJJREFUeNrt1DENADAMBLEnUWYNfyplkCWRuvgAeLyk7VTdTAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAoK+GAQCALcCRAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAPATeIhyLZUinFFhAAAAAElFTkSuQmCC);background-size:50%;background-position:center;background-repeat:no-repeat}.fileControl .addButton.working{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAMgAAADIAQMAAACXljzdAAAACXBIWXMAAAsTAAALEwEAmpwYAAAAB3RJTUUH3wcJCgwL1mSEkgAAABl0RVh0Q29tbWVudABDcmVhdGVkIHdpdGggR0lNUFeBDhcAAAADUExURQAAAKd6PdoAAAAcSURBVBgZ7cGBAAAAAMOg+1NP4QDVAAAAAABOARRQAAHaHhFoAAAAAElFTkSuQmCC)}.fileControl .item{position:relative;display:inline-block;vertical-align:top;margin-right:10px;margin-bottom:5px;cursor:pointer}.fileControl .item.image{background-color:rgba(200,200,200,.2);background-size:contain;background-repeat:no-repeat;background-position:center;width:100px;height:100px}.fileControl .item.file{height:100px;width:80px;background-color:rgba(140,140,140,.2);border-top-right-radius:20px}.fileControl .item.file div.fileExtension{position:absolute;background-color:#323232;color:#fff;right:-5px;bottom:5px;padding-left:10px;padding-right:10px;padding-top:4px;padding-bottom:4px;box-shadow:2px 2px 3px rgba(100,100,100,.6)}.fileControl .item.file div.fileExtension.pdf{background-color:red}.fileControl .item.file div.fileExtension.xls,.fileControl .item.file div.fileExtension.xlsx{background-color:#0b0}.fileControl .item.file div.fileExtension.doc,.fileControl .item.file div.fileExtension.docx{background-color:#00b}.fileControl .item.file div.fileExtension.ai,.fileControl .item.file div.fileExtension.esp{background-color:#db6606}.fileControl .item.file div.fileExtension.psd{background-color:#298ced}.fileControl .item.file div.fileExtension.ppt,.fileControl .item.file div.fileExtension.pptx{background-color:#ff8458}.fileControl .addButton,.fileControl .item .image{width:100px;height:100px;user-select:none}@media screen and (max-width:400px){.fileControl .addButton,.fileControl .item.file,.fileControl .item.image{width:calc((100% / 3) - 10px);height:inherit;padding-bottom:calc((100% / 3) - 10px)}}.fileControl .item .confirmDelete{background-color:rgba(187,0,0,.8);color:#fff;cursor:pointer;position:absolute;display:-webkit-flex;display:flex;height:100%;width:100%;-webkit-flex-direction:row;-moz-flex-direction:row;-ms-flex-direction:row;flex-direction:row}.fileControl .item .confirmDelete>span{display:block;-webkit-flex:1 1 auto;flex:1 1 auto;line-height:100%;font-size:14px;text-align:center;user-select:none;cursor:pointer;align-self:center}.checkBoxControl{margin-bottom:10px;font-size:16px;padding-top:5px}.checkBoxControl input{margin-right:5px;-webkit-appearance:none;-moz-appearance:none;outline:0;box-shadow:none;border:1px solid #000;background-color:#fff;width:15px;height:15px;vertical-align:middle;border-radius:0}.checkBoxControl input:checked{background-color:rgba(0,0,0,.8);border:1px solid #000;background-image:none}.checkBoxControl label{vertical-align:middle} div.legacy{line-height:160%}div.legacy h1{font-size:1.2em;margin-top:1em;margin-bottom:.5em;font-family:OpenSans-SemiBold;color:#000}@media screen and (min-width:800px){div.legacy{line-height:170%}}#lightboxOverlay{position:fixed;top:0;left:0;bottom:0;right:0;z-index:9999;background-color:#000;opacity:.85;display:none}#lightbox{position:absolute;left:0;width:100%;z-index:10000;text-align:center;line-height:0;font-family:"lucida grande",tahoma,verdana,arial,sans-serif;font-weight:400}#lightbox img{max-width:100%;max-height:100%}#lightbox a img{border:none}.lb-outerContainer{position:relative;background-color:#fff;width:500px;height:500px;margin:0 auto;-webkit-border-radius:4px;-moz-border-radius:4px;-ms-border-radius:4px;-o-border-radius:4px;border-radius:4px}.lb-outerContainer:after{content:"";display:table;clear:both}.lb-container{padding:10px}.lb-loader{position:absolute;top:40%;left:0;height:25%;width:100%;text-align:center;line-height:0}.lb-nav{position:absolute;top:0;left:0;height:100%;width:100%;z-index:10}.lb-container>.nav{left:0}.lb-nav a{outline:0}.lb-next,.lb-prev{width:49%;height:100%;background-image:url("data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7");display:block}.lb-prev{left:0;float:left}.lb-next{right:0;float:right}.lb-prev:hover{background:url(./images/prev.png) left 48% no-repeat}.lb-next:hover{background:url(./images/next.png) right 48% no-repeat}.lb-dataContainer{margin:0 auto;padding-top:5px;width:100%;-moz-border-radius-bottomleft:4px;-webkit-border-bottom-left-radius:4px;-ms-border-bottom-left-radius:4px;-o-border-bottom-left-radius:4px;border-bottom-left-radius:4px;-moz-border-radius-bottomright:4px;-webkit-border-bottom-right-radius:4px;-ms-border-bottom-right-radius:4px;-o-border-bottom-right-radius:4px;border-bottom-right-radius:4px}.lb-dataContainer:after{content:"";display:table;clear:both}.lb-data{padding:0 10px;color:#bbb}.lb-data .lb-details{width:85%;float:left;text-align:left;line-height:1.1em}.lb-data .lb-caption{font-size:13px;font-weight:700;line-height:1em}.lb-data .lb-number{display:block;clear:left;padding-bottom:1em;font-size:11px}.lb-data .lb-close{width:35px;float:right;padding-bottom:.7em;outline:0}.lb-data .lb-close:hover{cursor:pointer}
Cardiovasculaire Geneeskunde.nl

Wat betekent de komst van het eerste NOAC antidotum voor de klinische praktijk?

Slides (presentatie) - 18 jan. 2016


Slides gepresenteerd door dr. Michiel Coppens (AMC, Amsterdam) tijdens de CVGK Focus opname over de implicaties van de komst van het eerste antidotum voor de klinische praktijk.

CVGK 10 dec 2015 slides.pdf (0,5MB)CVGK 10 dec 2015 slides.pdf (0,5MB)
 

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: